Maze Therapeutics Inc [MAZE] stock is trading at $44.27, down -4.18%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The MAZE shares have gain 11.20% over the last week, with a monthly amount glided 5.45%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Maze Therapeutics Inc [NASDAQ: MAZE] stock has seen the most recent analyst activity on December 04, 2025, when Wells Fargo initiated its Overweight rating and assigned the stock a price target of $55. On September 02, 2025, BTIG Research initiated with a Buy rating and assigned a price target of $30 on the stock. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $34 on July 23, 2025. Wedbush initiated its recommendation with a Outperform and recommended $17 as its price target on July 08, 2025.
Maze Therapeutics Inc [MAZE] stock has fluctuated between $6.71 and $46.80 over the past year. Currently, Wall Street analysts expect the stock to reach $51 within the next 12 months. Maze Therapeutics Inc [NASDAQ: MAZE] shares were valued at $44.27 at the most recent close of the market. An investor can expect a potential return of 15.2% based on the average MAZE price forecast.
Analyzing the MAZE fundamentals
Maze Therapeutics Inc [NASDAQ:MAZE] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.45 and Total Capital is -0.34. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Maze Therapeutics Inc’s Current Ratio is 17.70. Further, the Quick Ratio stands at 17.70, while the Cash Ratio is 14.33.
Transactions by insiders
Recent insider trading involved SEKAR KATHIRESAN, Former Director, that happened on Jan 16 ’26 when 29772.0 shares were purchased. President, R&D & CMO, Bernstein Harold completed a deal on Jan 07 ’26 to sell 25156.0 shares. Meanwhile, Director Sohn Catherine A. sold 26920.0 shares on Jan 07 ’26.
